ACM
NMTR

Altium Capital Management’s 9 Meters Biopharma NMTR Stock Holding History

Altium Capital Management’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-63,250
Closed -$1.09M – 145
2020
Q4 		$1.09M Buy
+63,250
New +$1.06M 0.41% 80

Other funds holding NMTR

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Altium Capital Management's NMTR Position: Q1 2021 in Review

Altium Capital Management sold out of 9 Meters Biopharma (NMTR) in Q1 2021, closing a stake of 63,250 shares — an estimated $1.09M sold.

Altium Capital Management first reported a position in NMTR in Q4 2020 and held it in 1 quarter. The position peaked at $1.09M in Q4 2020. 90 funds tracked by Wall St. Rank hold NMTR as of Q1 2021.

  • Altium Capital Management reported no remaining 9 Meters Biopharma position as of Q1 2021 after selling out during the quarter.
  • Altium Capital Management sold 63,250 9 Meters Biopharma shares in Q1 2021, an estimated $1.09M.
  • Altium Capital Management first reported a position in 9 Meters Biopharma in Q4 2020 and held it in 1 quarter.
  • Altium Capital Management's 9 Meters Biopharma position peaked at $1.09M in Q4 2020.
  • 90 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q1 2021.

Based on Altium Capital Management's 13F filing for Q1 2021, filed 6 May 2021.